Cite
HARVARD Citation
Goll, G. et al. (2019). Long‐term efficacy and safety of biosimilar infliximab (CT‐P13) after switching from originator infliximab: open‐label extension of the NOR‐SWITCH trial. Journal of internal medicine. pp. 653-669. [Online].